Therefore, the combination of RTKis and AKTi was more efficient than high doses of AKTi to completely inhibit the AKT phosphorylation and the growth of the KRAS or BRAF mutant CRC cells. The gene discussed is BRAF; the disease is colorectal carcinoma.